Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma
Lucie M. Heinzerling, Margarete Urbanek, Jens O. Funk, Stefan Peker, Oliver Bleck, Karsten Neuber, Günter Burg, Peter von den Driesch, Reinhard DummerVolume:
89
Year:
2000
Language:
english
Pages:
10
DOI:
10.1002/1097-0142(20001015)89:83.0.co;2-h
File:
PDF, 687 KB
english, 2000